Last Updated: 15 Sep 2024
Executive Summary
Sanofi ADR (SNY) is a global healthcare company with a market capitalization of $143.2 billion. The company has a strong financial position with an EBITDA of $11.75 billion and a profit margin of 8.95%. Sanofi ADR is currently trading at $57.13, which is below its 52-week high of $58.97. The company has a forward PE ratio of 11.72, which is attractive compared to the industry average. Analysts have a strong buy rating on the stock, with a target price of $59.89.
Company Overview
Sanofi ADR is a global healthcare company that is engaged in the research, development, manufacture, and marketing of therapeutic solutions. The company has a diversified portfolio of products that includes pharmaceuticals, vaccines, and consumer healthcare products. Sanofi ADR has a strong presence in Europe, North America, and Asia. The company is headquartered in Paris, France.
Fundamental Analysis
Sanofi ADR has a strong financial position. The company has an EBITDA of $11.75 billion and a profit margin of 8.95%. The company's revenue has grown by 7.5% over the past year. Sanofi ADR has a strong balance sheet with $13.5 billion in cash and equivalents. The company's debt-to-equity ratio is 0.5, which is below the industry average.
Technical Analysis
Sanofi ADR is currently trading at $57.13, which is below its 52-week high of $58.97. The stock has been trading in a range between $52.63 and $58.97 over the past year. The stock's 50-day moving average is $53.54 and its 200-day moving average is $49.7. The stock's relative strength index (RSI) is 52.3, which indicates that the stock is neither overbought nor oversold.
Short Term Outlook
Sanofi ADR is expected to continue to trade in a range between $52.63 and $58.97 in the short term. The stock's technical indicators are neutral, which suggests that the stock is not likely to make a significant move in either direction in the near term.
Long Term Outlook
Sanofi ADR is a well-positioned company with a strong financial position and a diversified portfolio of products. The company is expected to continue to grow in the long term. The company's forward PE ratio of 11.72 is attractive compared to the industry average. Analysts have a strong buy rating on the stock, with a target price of $59.89.
Analyst Recommendations
Analysts have a strong buy rating on Sanofi ADR. The consensus target price is $59.89. Three analysts have a strong buy rating on the stock, three analysts have a buy rating, and zero analysts have a hold, sell, or strong sell rating.
